These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 21829066)

  • 21. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
    Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
    Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
    Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
    Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
    J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
    Tyagi P; Grothey A
    Clin Colorectal Cancer; 2006 Nov; 6(4):261-4. PubMed ID: 17241510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
    Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M; Hoshino S; Noda N; Nakano M; Matsuo K; Yamauchi Y; Shinohara T; Tanaka S; Yamashita Y
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):83-8. PubMed ID: 20087037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
    Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
    J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
    Shitara K; Matsuo K; Takahari D; Yokota T; Inaba Y; Yamaura H; Sato Y; Najima M; Ura T; Muro K
    Eur J Cancer; 2009 Jul; 45(10):1757-63. PubMed ID: 19217278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
    Petrioli R; Paolelli L; Marsili S; Civitelli S; Francini E; Cioppa T; Roviello F; Nettuno R; Intrivici C; Tanzini G; Lorenzi M; Francini G
    Oncology; 2006; 70(5):345-50. PubMed ID: 17179728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.